Enzymatic differences between chronic lymphocytic leukemia and prolymphocytic leukemia

Ratech, Howard; Borer, William Z.; Winberg, Carl D.; Rappaport, Henry

doi:10.1016/0145-2126(85)90156-0

Cited by 5 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from slight fluctuations no significant variations in the enzyme patterns were found. Low levels of ADA and PNP in B-CLL have also been reported by other authors (Gan et af., 1982, La Mantia et al, 1977Quagliata et al, 1974;Ratech et al, 1985;Van Laarhoven et al, 1983;Vertongen er al., 1984). They have also found that most patients with B-CLL have low levels of 5 " T .…”

Section: Resultsmentioning

confidence: 99%

“…Unfortunately only a few patients with CC and PLL were available for study. Ratech et al (1985) determined ADA and PNP levels in four patients with PLL and seven patients with CLL and suggested that PNP levels were elevated in PLL. Even though we have also found higher PNP activities in PLL, we do not think that a statistical analysis for this group was appropriate as only four patients with PLL were available for study.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia

Knauf

Ganeshaguru

et al. 1987

Hematological Oncology

View full text Add to dashboard Cite

Previous reports have shown that the purine degradative enzymes adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP) and ecto-5'-nucleotidase (5'NT), play an important role in the normal development of lymphocytes and that investigations of these enzymes are of value in defining subsets of lymphoid malignancies of T-cell origin. Pharmacological inhibition of one of these enzymes has been found to be an effective treatment for a few lymphatic neoplasia. We have studied the activities of the above enzymes in the circulating malignant cells of 25 patients with B-chronic lymphatic leukemia (B-CLL), four patients with B prolymphocytic leukemia (PLL), seven patients with leukemic centrocytic lymphoma (CC), 18 patients with hairy cell leukemia (HCL) and 16 patients with immunocytoma (IC). For comparison, the blasts of nine patients with 'common' acute lymphatic leukemia (cALL) and normal T (n = 12) and B (n = 8) cells were simultaneously investigated. Despite morphologic similarity, the leukemic cells of the chronic B cell malignancies demonstrate different enzyme patterns. B-CLL is characterized by very low activities of all the enzymes ADA, PNP and 5'NT. In the cells of HCL the highest values of PNP are found. The leukemic cells of IC are characterized by low levels of ADA but moderate levels of PNP and high levels of 5'NT. Thus some of the entities of B malignancies show typical enzyme patterns which might be of importance in defining maturation stages of the disease. The differences in these enzyme patterns can also be made use of in therapy with enzyme inhibitors such as deoxycoformycin.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia

Knauf

Ganeshaguru

et al. 1987

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…The enzyme patterns in "common" acute lymphocytic leukemia (cALL, pre-B phenotype) and B-cell chronic lymphocytic leukemia (CLL) have been studied extensively [22,36,59,60,62,74,79,82]. The lymphoblasts of cALL are characterized by high concentrations of ADA and 5NT but low levels of PNP [22, 62,74].…”

Section: Normal and Neoplastic B-cellsmentioning

confidence: 99%

“…The lymphoblasts of cALL are characterized by high concentrations of ADA and 5NT but low levels of PNP [22, 62,74]. The cells of B-CLL have typically low to nondetectable levels of ADA and PNP [59,60,79,82]. Most patients with B-CLL also have low concentrations of 5NT.…”

Section: Normal and Neoplastic B-cellsmentioning

confidence: 99%

“…The malignant cells of hairy-cell leukemia have the highest levels of PNP [37] and those of immunocytoma the highest concentrations of 5NT [36]. Cells of B-prolymphocytic leukemia seem to have higher levels of PNP than B-CLL [60], whereas neoplastic plasma cells from patients with multiple myeloma have the highest levels of both PNP and 5NT (Ho et al, unpublished results). These results suggest that with B-cell maturation the activities of PNP and 5NT also increase.…”

Section: Normal and Neoplastic B-cellsmentioning

confidence: 99%

See 1 more Smart Citation

Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors

Ganeshaguru

1988

Klin Wochenschr

View full text Add to dashboard Cite

A few enzymes of the purine degradative pathway have proved valuable in diagnosis and treatment of lymphomas and lymphocytic leukemia. Of particular interest are the enzymes adenosine deaminase (ADA), purine nucleoside phosphorylase (PNP) and ecto-5'-nucleotidase (5NT). Intact activities of ADA and PNP have been shown to be vital for lymphoid cells. During development, lymphoid precursors go through remarkable changes in the concentrations of these enzymes and the neoplasms derived from them show a "frozen" biochemical profile similar to the corresponding normal cell of origin. Knowledge of the role of these enzymes has led to the pharmacological use of enzyme inhibitors for the specific treatment of lymphoid neoplasms. This review concerns the enzymatic make-up of normal and neoplastic lymphocytes and exploitation of this knowledge for the treatment of lymphomas. Special emphasis will be put on the clinical use of an ADA-inhibitor, deoxycoformycin.

show abstract

Biochemical, Immunological, and Molecular Markers of Hemopoietic Precursor Cells

Bonati

1991

Blood Cell Biochemistry

View full text Add to dashboard Cite

Enzymatic differences between chronic lymphocytic leukemia and prolymphocytic leukemia

Cited by 5 publications

References 14 publications

Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia

Purine degradative enzymes in circulating malignant cells of patients with chronic B cell neoplasia

Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors

Biochemical, Immunological, and Molecular Markers of Hemopoietic Precursor Cells

Contact Info

Product

Resources

About